Not So Different: Goodwin Attorneys Discuss Updates to Biosimilars Litigation Guide

March 07, 2021

Key 2020-2021 updates to the Guide to Biosimilars litigation and Regulation in the US encompass antitrust litigation, preliminary injunctions, and a slowdown in litigation.

Minnesota Moves to Override Payer Preferences on Biosimilars
ACCC Virtual: Dr Wilfong of Texas Oncology Discusses Biosimilar Integration
The Top 5 Biosimilar Articles for the Week of March 1
Study: Biosimilar vs Originator Spending on Comparative Efficacy Trials